We narrowed to 61,650 results for: ran

#175274-AAV1

Ready-to-use AAV1 particles produced from pAAV-rtTA (#175274). In addition to the viral particles, you will also receive purified pAAV-rtTA plasmid DNA. Syn-driven expression of reverse tetracycline-controlled transactivator. These AAV preparations are suitable purity for injection into animals.

Wei Xu

Li et al Nat Methods. 2021 Nov 25. pii: 10.1038/s

Jan. 15, 2026

Academic Institutions and Nonprofits only

#1000000155

For rapid modular cloning of adenoviral, lentiviral, PiggyBac and Sleeping Beauty transposon vectors for transgene or RNAi delivery (pMVP) and dCas9-based epigenetic engineering (pMAGIC).

Christopher Newgard

Sept. 6, 2019

Academic Institutions and Nonprofits only

#163509-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP11839-pAAV-hSyn1-SYFP2-10aa-H2B-WPRE3-BGHpA (Alias: CN1839) (#163509). In addition to the viral particles, you will also receive purified AiP11839-pAAV-hSyn1-SYFP2-10aa-H2B-WPRE3-BGHpA (Alias: CN1839) plasmid DNA. hSyn1-driven expression for nuclear SYFP2 labeling in neurons. Useful for nuclear isolation and scRNA-seq applications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 17, 2022

Academic Institutions and Nonprofits only

#163505-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP11390-pAAV-DLX2.0-minBG-SYFP2-WPRE3-BGHpA (Alias: CN1390) (#163505). In addition to the viral particles, you will also receive purified AiP11390-pAAV-DLX2.0-minBG-SYFP2-WPRE3-BGHpA (Alias: CN1390) plasmid DNA. AAV vector for strong and rapid SYFP2 expression in forebrain GABAergic interneurons. The enhancer core sequence has 100% sequence conservation between mouse and human. Developed especially for rapid viral labeling in human and NHP organotypic brain slice culture. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 17, 2022

Academic Institutions and Nonprofits only

#213943-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV5

Ready-to-use AAV5 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213939-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213947-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 29, 2025

Academic Institutions and Nonprofits only

#213859-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#230681-AAV5

Ready-to-use AAV5 particles produced from AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA (#230681). In addition to the viral particles, you will also receive purified AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA plasmid DNA. minBG-driven expression of iCre recombinase in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 6, 2025

Academic Institutions and Nonprofits only

#224043-AAV8

Ready-to-use AAV8 particles produced from AiP14467 - pAAV-AiE2182m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN4467) (#224043). In addition to the viral particles, you will also receive purified AiP14467 - pAAV-AiE2182m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN4467) plasmid DNA. minBG-driven expression of SYFP2 in cortical L5_IT neurons (strong). These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Feb. 9, 2026

Academic Institutions and Nonprofits only

#224006-AAV8

Ready-to-use AAV8 particles produced from AiP12828 - pAAV-AiE0456m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2828) (#224006). In addition to the viral particles, you will also receive purified AiP12828 - pAAV-AiE0456m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2828) plasmid DNA. minBG-driven expression of SYFP2 in cortical L5_ET neurons. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Feb. 9, 2026

Academic Institutions and Nonprofits only

#230804-AAV1

Ready-to-use AAV1 particles produced from AiP20168 - pAAV-AiE2575m-minBG-iCre-WPRE3-BGHpA (#230804). In addition to the viral particles, you will also receive purified AiP20168 - pAAV-AiE2575m-minBG-iCre-WPRE3-BGHpA plasmid DNA. minBG-driven expression of iCre in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Feb. 9, 2026

Academic Institutions and Nonprofits only

#213940-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_dTomato_nlsdTomato (#213940). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213944-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213814-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_dTomato_nlsdTomato (#213814). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only